4:32 AM
Feb 27, 2018
 |  BioCentury  |  Emerging Company Profile

Stressing out cancer

Quentis launches from Glimcher lab with $48M to target ER stress in cancer

Quentis Therapeutics Inc. debuted with a $48 million series A round to develop potentially first-in-class therapies that inhibit the ER stress response, with the dual effect of killing tumor cells directly and unleashing immune cells in the tumor microenvironment.

The company is based on findings from the lab of Laurie Glimcher, president and CEO of Dana-Farber Cancer Institute, who is a co-founder of the newco. Glimcher’s studies have focused on the stress response since her tenure at Weill Cornell Medical College.

Environmental conditions such as nutrient deprivation, hypoxia and oxidative stress lead to the accumulation of unfolded or misfolded proteins in the endoplasmic reticulum (ER), triggering a state of ER stress. Unmitigated ER stress results in apoptotic cell death.

Tumor cells thrive in these adverse conditions by relieving ER stress through activation...

Read the full 649 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD